If you have Cigna coverage and your gastroenterologist has prescribed Skyrizi for Crohn's disease, the practical question is whether your plan will pay and what you must do to clear the approval. The short answer is that Cigna does cover Skyrizi (risankizumab-rzaa) for Crohn's, but coverage runs through prior authorization rather than automatic approval. Skyrizi is an interleukin-23 antagonist that the FDA first approved in the United States in 2019, and it received its Crohn's disease indication on June 17, 2022. What follows is how Cigna's coverage mechanics work and how to read your own plan documents, since the terms of your specific benefit plan ultimately control.
How Cigna Manages Skyrizi Coverage
Cigna administers pharmacy benefits in partnership with Express Scripts, and it dispenses specialty biologics like Skyrizi through Accredo, a Cigna Healthcare specialty pharmacy. That structure matters for Skyrizi because the treatment touches two parts of your benefit. Skyrizi for Crohn's uses a three-dose intravenous induction regimen of 600 mg at Weeks 0, 4, and 8, followed by subcutaneous maintenance of 180 mg or 360 mg at Week 12 and every 8 weeks thereafter. The intravenous induction may process under the medical benefit while the subcutaneous maintenance pens process under the pharmacy benefit, so two separate authorizations can apply. Knowing which benefit each phase falls under helps you anticipate where a delay might occur and who to call.
What Cigna's Coverage Policy Requires
Cigna publishes its criteria openly. Prior authorization is required for benefit coverage of Skyrizi intravenous, and prior authorization is recommended for the subcutaneous product as well. For Crohn's disease, Cigna's subcutaneous policy approves initial therapy for six months when the patient is at least 18 years old, the prescriber confirms intravenous induction will occur within three months, and the prescription comes from or in consultation with a gastroenterologist. Notably, the current Crohn's criteria do not list a mandatory trial of a preferred anti-tumor necrosis factor agent before Skyrizi. Cigna's policy notes that the ACG and AGA 2025 Crohn's guidelines recommend upfront use of advanced therapies rather than step-up therapy after corticosteroid or immunomodulator failure. Even so, formularies and step-therapy rules vary by employer plan, so confirm your own version.
The Clinical Evidence Behind the Indication
Cigna's coverage rests on the same trial program the FDA reviewed. The phase 3 ADVANCE and MOTIVATE induction trials randomized patients with moderately to severely active Crohn's disease to intravenous risankizumab or placebo at weeks 0, 4, and 8. In ADVANCE, clinical remission at week 12 reached 45% with the 600 mg dose versus 25% with placebo, and MOTIVATE showed 42% versus 20%. Maintenance was tested separately in the phase 3 FORTIFY withdrawal trial, which evaluated subcutaneous risankizumab at 180 mg and 360 mg over 52 weeks in patients who had responded to induction. This is why Cigna's policy ties a subcutaneous initial approval to confirmed intravenous induction. The two phases work as one regimen, and your authorization paperwork should reflect that sequence clearly.
How to Confirm Your Own Coverage
Because a benefit plan document always supersedes the general coverage policy, you should verify three things specific to your plan. Start by locating your formulary tier for Skyrizi and the prior authorization requirement attached to it, then check whether your plan adds step therapy that the national policy does not impose.
Your plan's drug list, to see Skyrizi's tier and any utilization controls
Your medical and pharmacy benefit split, to know where induction and maintenance process
Your prior authorization status, which your gastroenterologist's office can submit and track
Cigna's standard turnaround for a prescription drug coverage request is roughly five business days, so build that into your timeline. If Accredo will dispense your maintenance doses, expect onboarding calls to schedule shipments and verify your benefit before the first pen arrives.
Building a Strong Authorization and Handling Denials
A clean prior authorization for Skyrizi in Crohn's usually moves faster when the submission documents your diagnosis, disease severity, and prior treatments. Cigna's renewal criteria for established patients look for evidence of benefit, including objective measures such as fecal calprotectin, C-reactive protein, endoscopic assessment, or a reduced corticosteroid dose, or symptom improvement like reduced pain, stool frequency, or blood in stool. Capturing those data points from the start makes both the initial request and any future renewal easier to support. If Cigna denies the request, you have the right to appeal, and a strong appeal restates the medical-necessity case against the exact criteria in the published policy. Your gastroenterologist can request a peer-to-peer review with a Cigna medical director, and you can escalate through internal and then external review if needed.
The Bottom Line for Cigna Members
Cigna covers Skyrizi for Crohn's disease, with prior authorization as the gate rather than an outright barrier. The coverage policy approves initial therapy for adults when a gastroenterologist is involved and intravenous induction is planned, and it renews coverage when objective or symptomatic improvement is documented. Because induction and maintenance can split across the medical and pharmacy benefits administered through Express Scripts and Accredo, the smoothest path is to confirm your formulary tier, your benefit split, and your authorization status early. When the paperwork matches Cigna's stated criteria, approval is the expected outcome, and a documented treatment history gives you the strongest footing if you ever need to appeal.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.